Stockscreener 앱 받기
41.49
1.59%
-0.67
시간 외 거래:
41.49
전일 마감가:
$42.16
열려 있는:
$42.34
하루 거래량:
455.57K
Relative Volume:
1.05
시가총액:
$1.80B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-296.36
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
+2.98%
1개월 성능:
+6.41%
6개월 성능:
+55.39%
1년 성능:
+95.62%
1일 변동 폭
$41.38
$42.93
1주일 범위
$39.61
$42.93
52주 변동 폭
$17.82
$42.93
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
41.49 | 3.20B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-29 | 개시 | TD Cowen | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 12,470 Shares of Stock - MarketBeat
SG Americas Securities LLC Acquires 127,126 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharma COO Tessari sells shares worth $514,224 - Investing.com India
Kiniksa Pharma COO Tessari sells shares worth $514,224 By Investing.com - Investing.com UK
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week HighTime to Buy? - MarketBeat
Los Angeles Capital Management LLC Sells 36,570 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Savant Capital LLC Invests $398,000 in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Mark Ragosa Sells 19,900 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Rides ARCALYST Growth To Outpace The S&P 500 - Finimize
Exploring High Growth Tech Stocks in the US Market - Yahoo Finance
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London - The Manila Times
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Increases 5.3% This Week, Taking Five-year Gains to 166% - 富途牛牛
Kiniksa (NASDAQ: KNSA) to present at Jefferies Healthcare Conf.; live webcast Nov. 17 - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Has $17.26 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Acadian Asset Management LLC - MarketBeat
Fox Run Management L.L.C. Buys 24,391 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Vanguard Group Inc Reduces Stake in Kiniksa Pharmaceuticals Inte - GuruFocus
John Paolini Sells 82,542 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates - MSN
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Kiniksa Pharmaceuticals CMO Sells Shares - TradingView
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript - Insider Monkey
Y Intercept Hong Kong Ltd Buys New Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Asset Management One Co. Ltd. Boosts Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat
Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com Australia
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
New Strong Sell Stocks for Oct. 30th - The Globe and Mail
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction - Finimize
Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Kiniksa Pharmaceuticals International, plc SEC 10-Q Report - TradingView
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighHere's Why - MarketBeat
Key Developments in KNSA Revenue Forecasts - GuruFocus
Q3 2025 Earnings Call - MarketScreener
KNSA Surpasses Revenue Expectations and Updates Sales Forecast - GuruFocus
Kiniksa Pharmaceuticals Swings to Q3 Net Income, Revenue Increases - MarketScreener
Kiniksa Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Esti - GuruFocus
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32 - MarketScreener
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc Reports Q3 Revenue $180.9M, vs. FactSet Est of $167.4M - MarketScreener
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results - TradingView
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.17%
0.67%
자본화:
|
볼륨(24시간):